MA46278A - Molécules de liaison qui modulent une activité biologique exprimée par une cellule - Google Patents

Molécules de liaison qui modulent une activité biologique exprimée par une cellule

Info

Publication number
MA46278A
MA46278A MA046278A MA46278A MA46278A MA 46278 A MA46278 A MA 46278A MA 046278 A MA046278 A MA 046278A MA 46278 A MA46278 A MA 46278A MA 46278 A MA46278 A MA 46278A
Authority
MA
Morocco
Prior art keywords
cell
biological activity
binding molecules
activity expressed
modulate biological
Prior art date
Application number
MA046278A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Ton Logtenberg
Paulus Johannes Tacken
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA46278A publication Critical patent/MA46278A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA046278A 2016-09-23 2017-09-22 Molécules de liaison qui modulent une activité biologique exprimée par une cellule MA46278A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16190499 2016-09-23

Publications (1)

Publication Number Publication Date
MA46278A true MA46278A (fr) 2019-07-31

Family

ID=57132987

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046278A MA46278A (fr) 2016-09-23 2017-09-22 Molécules de liaison qui modulent une activité biologique exprimée par une cellule

Country Status (17)

Country Link
US (1) US11685786B2 (fr)
EP (2) EP4342912A3 (fr)
JP (2) JP7305538B2 (fr)
KR (1) KR20190065318A (fr)
CN (2) CN109983033B (fr)
AU (2) AU2017332452B2 (fr)
BR (1) BR112019005895A2 (fr)
CA (1) CA3038020A1 (fr)
EA (1) EA201990578A1 (fr)
IL (2) IL265541B1 (fr)
MA (1) MA46278A (fr)
MX (1) MX2019003241A (fr)
NZ (1) NZ751956A (fr)
PH (1) PH12019550044A1 (fr)
TW (1) TW201920653A (fr)
UA (1) UA127449C2 (fr)
WO (1) WO2018056821A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202001779UA (en) 2015-01-20 2020-04-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
RU2018142573A (ru) 2016-06-20 2020-07-21 Ф-Стар Бета Лимитед Партнеры по связыванию lag-3
EP3472207B1 (fr) 2016-06-20 2021-01-20 F-Star Delta Limited Molécules de liaison liant pd-l1 et lag-3
SG11201811431VA (en) 2016-07-14 2019-01-30 Genmab As Multispecific antibodies against cd40 and cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
UA127449C2 (uk) 2016-09-23 2023-08-30 Мерус Н.В. Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
EP3649156A1 (fr) * 2017-07-06 2020-05-13 Merus N.V. Anticorps qui modulent une activité biologique exprimée par une cellule
JP7290013B2 (ja) 2017-08-04 2023-06-13 ジェンマブ エー／エス Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
TW201930355A (zh) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 結合物件(三)
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
US11827672B2 (en) 2018-03-30 2023-11-28 Eureka Therapeutics, Inc. Constructs trageting CD22 and uses thereof
EA202092420A1 (ru) * 2018-04-09 2021-01-28 Ориджинселл Терапьютикс Ко., Лтд. Антитело против pd-l1 и его применение
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
MX2021000398A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a pd-l1 y cd137.
EP3636320A1 (fr) * 2018-10-09 2020-04-15 Numab Therapeutics AG Anticorps dirigés contre cd137 et leurs procédés d'utilisation
SG11202103503WA (en) * 2018-10-09 2021-05-28 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
CA3118789A1 (fr) * 2018-11-06 2020-05-14 Genmab A/S Formulation d'anticorps
AU2020276500A1 (en) * 2019-05-10 2021-12-16 Lyvgen Biopharma Holdings Limited Humanized anti-CD137 antibodies and uses thereof
CA3144617A1 (fr) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Anticorps pour l'activation de lymphocytes t
JP2022553922A (ja) * 2019-10-11 2022-12-27 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
CN115135344A (zh) * 2020-02-04 2022-09-30 健玛保 在疗法中使用的抗体
CN115279403A (zh) * 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
WO2021222074A1 (fr) * 2020-04-28 2021-11-04 Ohio University Procédés pour prolonger la durée de conservation de sang et/ou de globules rouges donnés stockés et compositions de globules rouges traités ainsi produites
CN116462766A (zh) 2020-05-21 2023-07-21 美勒斯公司 用于生产ig样分子的方法和手段
KR20230048059A (ko) * 2020-07-31 2023-04-10 추가이 세이야쿠 가부시키가이샤 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
CN113416249B (zh) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
IL303634A (en) 2020-12-16 2023-08-01 Merus Nv Multispecific antibodies for cancer treatment
CN117157323A (zh) 2021-03-31 2023-12-01 美勒斯公司 新型多特异性抗体
WO2023146394A1 (fr) 2022-01-25 2023-08-03 Merus N.V. Polythérapie pour le traitement du cancer
US20230416396A1 (en) * 2022-05-18 2023-12-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
MXPA02007473A (es) * 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101163501A (zh) * 2005-02-23 2008-04-16 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP3456190B1 (fr) 2008-06-27 2021-11-24 Merus N.V. Animal murin transgéniques produisant un anticorps
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
WO2011161244A1 (fr) 2010-06-25 2011-12-29 Vaccibody As Structures protéiniques homodimères
EP2614082B1 (fr) 2010-09-09 2018-10-03 Pfizer Inc Molécules de liaison 4-1bb
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
CN107252485A (zh) 2013-04-03 2017-10-17 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
NZ720161A (en) 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
EP3527587A1 (fr) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Thérapie combinée comprenant des agonistes de ox40 et des antagonistes de pd-l1
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
SG10202003171TA (en) 2015-01-08 2020-05-28 BioNTech SE Agonistic tnf receptor binding agents
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
CN107614522A (zh) * 2015-01-14 2018-01-19 指南针制药有限责任公司 多特异性免疫调节性抗原结合构建体
EP3268037B1 (fr) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Agonistes cd27
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
CA2986415A1 (fr) * 2015-05-21 2016-11-24 Alligator Bioscience Ab Anticorps anti-cd137
PE20180926A1 (es) * 2015-05-29 2018-06-08 Bristol Myers Squibb Co Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3359568B1 (fr) * 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Anticorps bispécifiques avec tétravalence pour un récepteur de tnf costimulant
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
US20200048345A1 (en) * 2015-12-28 2020-02-13 Innate Pharma Multispecific antigen binding proteins
WO2017123673A2 (fr) 2016-01-11 2017-07-20 Inhibrx Lp Protéines de fusion multivalentes et multispécifiques fixant ox40
BR112018013677A2 (pt) * 2016-01-11 2019-01-22 Inhibrx Inc proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
PE20190562A1 (es) * 2016-05-27 2019-04-22 Abbvie Biotherapeutics Inc Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral
WO2018045110A1 (fr) 2016-08-30 2018-03-08 Xencor, Inc. Anticorps immunomodulateurs bispécifiques qui se lient à des récepteurs de costimulation et de points de contrôle
UA127449C2 (uk) 2016-09-23 2023-08-30 Мерус Н.В. Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
NZ751956A (en) 2022-01-28
IL311603A (en) 2024-05-01
JP7305538B2 (ja) 2023-07-10
AU2021202085A1 (en) 2021-04-29
CN117510643A (zh) 2024-02-06
EP3515951A1 (fr) 2019-07-31
CN109983033A (zh) 2019-07-05
AU2017332452B2 (en) 2021-01-07
IL265541A (en) 2019-05-30
CN109983033B (zh) 2023-10-31
UA127449C2 (uk) 2023-08-30
BR112019005895A2 (pt) 2019-06-11
IL265541B1 (en) 2024-04-01
CA3038020A1 (fr) 2018-03-29
WO2018056821A1 (fr) 2018-03-29
MX2019003241A (es) 2019-11-12
JP2023116811A (ja) 2023-08-22
KR20190065318A (ko) 2019-06-11
US20200017595A1 (en) 2020-01-16
TW201920653A (zh) 2019-06-01
US11685786B2 (en) 2023-06-27
AU2017332452A1 (en) 2019-04-11
JP2019537429A (ja) 2019-12-26
WO2018056821A8 (fr) 2019-05-02
EP3515951B1 (fr) 2024-02-28
EA201990578A1 (ru) 2019-10-31
EP4342912A3 (fr) 2024-05-22
PH12019550044A1 (en) 2019-11-11
EP4342912A2 (fr) 2024-03-27

Similar Documents

Publication Publication Date Title
MA46278A (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
SG11202000014UA (en) Binding molecules that modulate a biological activity expressed by a cell
IL271833A (en) Antibodies that regulate biological activity expressed by a cell
ECSP18030970A (es) Proteínas de unión a pd-1 y métodos para usarlas
MA54760A (fr) Molécules de liaison qui inhibent la croissance d'un cancer
DK3292137T3 (da) Proteiner specifikke for cd137
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3259844T3 (da) Styresystem til qubit-kredsløbstilstandsændring
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
IL266827A (en) A ligand-binding molecule with the ability to adjust the binding activity
DK3197453T3 (da) Kimært protein
DK3188836T3 (da) Dna-syntese
DK3113595T3 (da) Jordbehandlingskæde til landbrug
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
FR3027415B1 (fr) Modulateur de phase electro­optique
GB201802573D0 (en) Therapeutic molecules that bind to LAG3
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
DK3555712T3 (da) Styreelektronik til flere elektrofiltre
DK3304059T3 (da) Nervekultursystem
MA49751A (fr) Agents antifongiques à activité améliorée en ph acide
DK3141518T3 (da) Ergonomisk hovedtøj til heste
DK3668965T3 (da) Biologisk methaniseringsreaktor
DK3354737T3 (da) System til cellefri proteinsyntese
DK3481179T3 (da) Kædehjul til gødningsskraber
DK3621950T3 (da) Trpv1-modulatorforbindelser